CEO of Cytori Therapeutics Inc (CYTX, Financial) Christopher J Calhoun buys 7,000 shares of CYTX on 05/18/2009 at an average price of $2.81 a share.
Cytori Therapeutics Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue also known as fat. The Company's preclinical investigational therapies target cardiovascular disease spine and orthopedic conditions gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Cytori Therapeutics Inc has a market cap of $97.1 million; its shares were traded at around $2.85 with and P/S ratio of 21.5.
Recent Trades of Cytori Therapeutics Inc by CEO:
Recent Trades of Cytori Therapeutics Inc by Directors and Officers:
Cytori Therapeutics Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue also known as fat. The Company's preclinical investigational therapies target cardiovascular disease spine and orthopedic conditions gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Cytori Therapeutics Inc has a market cap of $97.1 million; its shares were traded at around $2.85 with and P/S ratio of 21.5.
Recent Trades of Cytori Therapeutics Inc by CEO:
- Buy: CEO Christopher J Calhoun bought 7,000 shares of CYTX stock on 05/18/2009 at the average price of $2.81; the price of the stock has increased by 1.42% since.
Recent Trades of Cytori Therapeutics Inc by Directors and Officers:
- Buy: President - Asia Pacific Norio Seijiro Shirahama bought 2,500 shares of CYTX stock on 11/26/2008 at the average price of $1.92; the price of the stock has increased by 48.44% since.
- Buy: Director David Rickey bought 17,500 shares of CYTX stock on 11/21/2008 at the average price of $1.96; the price of the stock has increased by 45.41% since.
- Buy: Director David Rickey bought 13,449 more shares of CYTX stock on 11/20/2008 at the average price of $2.06; the price of the stock has increased by 38.35% since.
